to study its effects on the loss-of-function of N-glycosylation pathway on hair cell regeneration
as an endoplasmic reticulum (ER) α-glucosidase I and II inhibitor to study its effects on TMED3-cystic fibrosis transmembrane conductance regulator (CFTR) interaction
as an insect trehalase inhibitor in TREH inhibition bioassay
Biochem/physiol Actions
α-Glucosidase inhibitor
1-Deoxynojirimycin (DNJ) is a naturally occurring alkaloid azasugar or iminosugar. It is observed in mulberry leaves, Commelina communis, and bacterial strains including Bacillus and Streptomyces species. DNJ acts as an α-glucosidase inhibitor and exhibits anti-viral anti-diabetic, anti-inflammatory, anti-obesity, and antioxidant properties.
Mulberry 1-deoxynojirimycin (DNJ), a potent α-glycosidase inhibitor, has therapeutic potency in the suppression of postprandial blood glucose levels thereby possibly preventing diabetes mellitus. However, DNJ has a relatively short half-life in vivo (about 2 h). Therefore, several doses of mulberry
This study examines the possibility of directly producing and utilizing useful substances in the intestines of animals using anaerobic bacteria that can grow in the intestines of animals. A facultative anaerobe producing a large amount of α-glucosidase inhibitor was isolated
A spectrophotometric assay for glucosidase I using the synthetic trisaccharide alpha-D-Glc 1-->2 alpha-D-Glc 1-->3 alpha-D-Glc-O(CH2)8COOCH3 is reported. The terminal glucose is released from the substrate by the enzyme and quantitated using glucose oxidase, peroxidase, and o-dianisidine. The trisaccharide is specific
Frontiers in microbiology, 11, 531-531 (2020-05-07)
Zika virus (ZIKV), a vector-borne virus of the family Flaviviridae, continues to spread and remains a significant global public health threat. Currently, there are no approved vaccines or antivirals against ZIKV. We investigated the anti-ZIKV ability of three iminosugars with
Orphanet journal of rare diseases, 7, 102-102 (2012-12-29)
Previous studies have provided equivocal data on the use of miglustat as maintenance therapy in Gaucher disease type 1. We report findings from a clinical trial evaluating the effects of miglustat treatment in patients with stable type 1 Gaucher disease
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
